We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00522470
Recruitment Status : Completed
First Posted : August 29, 2007
Last Update Posted : May 9, 2008
Sponsor:
Information provided by:
Baskent University

Brief Summary:
We aimed to evaluate the effects of rosiglitazone on serum ghrelin and peptide yy levels in diabetic women.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Obesity Drug: rosiglitazone Phase 4

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels in Diabetic Women

Resource links provided by the National Library of Medicine

U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   45 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Criteria

Inclusion Criteria:

  • newly diagnosed, drug naive women with type 2 diabetes

Exclusion Criteria:

  • presence of severe cardiovascular disease (eg, New York Heart Association class III or IV congestive heart failure or a history of myocardial infarction or stroke)
  • presence of thyroid, pituitary, nutritional, hepatic, renal, or neoplastic disorders

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00522470


Locations
Turkey
Baskent University Hospital Department of Endocrinology
Ankara, Bahçelievler, Turkey, 06490
Sponsors and Collaborators
Baskent University
Investigators
Principal Investigator: Zehra Berberoglu, MD Baskent University Faculty of Medicine

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00522470     History of Changes
Other Study ID Numbers: KA 06/299
First Posted: August 29, 2007    Key Record Dates
Last Update Posted: May 9, 2008
Last Verified: May 2008

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Rosiglitazone
Hypoglycemic Agents
Physiological Effects of Drugs